MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Jahr

2014

Autoren

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Ziemssen T, Duda P; RESTORE.

Verlag

Neurology. 2014 Apr 29;82(17):1491-8.

Link

https://doi.org/10.1212/wnl.0000000000000355

MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

MSPEECH (multiple sclerosis monitoring through speech interaction in clinic and at home): a Living Lab study protocol for co-created, speech-based digital biomarkers in multiple sclerosis

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes

Peripheral redox biomarkers in multiple sclerosis: associations with phenotype, cognition, and fatigue

Neurofilament-Leichtkette (sNfL) als Instrument zur Beurteilung der Krankheitsaktivität und des Therapieansprechens bei Multipler Sklerose (MS)

From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis